Clinical Trial Update: Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial [Phase 1]

View source ↗

Summary

A Phase 1 study investigating FH-FOLR1 ST CAR T cells for advanced, refractory, or recurrent osteosarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• FH-FOLR1 ST CAR T Cells (folate receptor alpha-targeted CAR T cells)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Advanced Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Status: RECRUITING